Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obicetrapib in HeFH (BROOKLYN)
NCT05425745Phase 3Completed
- Sponsor
- NewAmsterdam Pharma
- Start
- Jul 2022
- Primary completion
- May 2024
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of obicetrapib in heterozygous familial hypercholesterolemia (HeFH), sponsored by NewAmsterdam Pharma. Started Jul 2022; status: completed.
02
Drugs
obicetrapib
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT05425745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05425745.